Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1

Clinical Cancer Research

Volumn 18, Issue 1, 2012, Pages 263-272

  Arnault, Jean Philippe ^a   Mateus, Christine ^a   Escudier, Bernard ^a   Tomasic, Gorana ^a   Wechsler, Janine ^a   Hollville, Emilie ^a   Soria, Jean Charles ^a   Malka, David ^a   Sarasin, Alain ^a   Larcher, Magalie ^b   Andrë, Jocelyne ^c   Kamsu Kom, Nyam ^a   Boussemart, Lise ^a   Lacroix, Ludovic ^a   Spatz, Alain ^d   Eggermont, Alexander M ^a   Druillennec, Sabine ^b   Vagner, Stephan ^a   Eychène, Alain ^b   Dumaz, Nicolas ^c   Robert, Caroline ^a   more..

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CURIE   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PLACEBO; RAF PROTEIN; RAS PROTEIN; SORAFENIB;

ADULT; AGED; ARTICLE; BENIGN SKIN TUMOR; CARCINOGENESIS; CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIMERIZATION; DNA EXTRACTION; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; FOLLICULITIS; GENE MUTATION; HAIR FOLLICLE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; KERATOACANTHOMA; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE AKT1; ONCOGENE BRAF; ONCOGENE EGFR; ONCOGENE H RAS; ONCOGENE KIRAS; ONCOGENE N RAS; ONCOGENE PI3KCA; ONCOGENE PTEN; ONCOGENE TGFBR1; ONCOGENE TP53; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CYST; SKIN DEFECT; SKIN INFLAMMATION; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION;

EID: 84855435059     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1344     Document Type: Article

References (41)

1. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8. (Pubitemid 46398669)
2. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34. (Pubitemid 46089673)
4. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-8.
5. Arnault JP, Wechsler J, Escudier B, Spatz A, Tomasic G, Sibaud V, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27:e59-61.
6. Autier J, Escudier B, Wechsler J, Spatz A, Robert C. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886-92. (Pubitemid 352039741)
7. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008;144:779-82. (Pubitemid 351846880)
8. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009;7:20-3.
9. Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007;56:171-2.
10. Robert C, Arnault J-P, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol 2011;23:177-82.
11. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006;66:9483-91. (Pubitemid 44623646)
12. Robert C, Soria JC, Spatz A, Le Cesne A, Malka D, Pautier P, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500. (Pubitemid 40903630)
13. Robert C, Spatz A, Faivre S, Armand J-P, Raymond E. Tyrosine kinase inhibition and grey hair. Lancet 2003;361:1056. (Pubitemid 36351380)
14. Robert C, Faivre S, Raymond E, Armand J-P, Escudier B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005;143:313-4. (Pubitemid 41134231)
15. Keeford R, Long G, Arkenau HT, Brown MP, Millward M, O'Day S, et al. Selective inhibition of oncogenic BRAF V600E/K/D byGSK2118436: evidence of clinical activity in subjects with metastatic melanoma. Pigment Cell Melanoma Res 2010;23:912.
16. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999;199:208-12.
17. Kossard S, Tan K-B, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008;30:127-34. (Pubitemid 351441984)
18. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993;15:332-42; discussion 343-352.
19. Goudie DR, D'Alessandro M, Merriman B, Lee H, Szeverënyi I, Avery S, et al. Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1. Nat Genet 2011;43:365-9.
20. Kossard S, Tan K-B, Choy C. Keratoacanthoma and infundibulocystic squamous cell carcinoma. Am J Dermatopathol 2008;30:127-34. (Pubitemid 351441984)
21. Yoshikawa K, Katagata Y, Kondo S. Relative amounts of keratin 17 are higher than those of keratin 16 in hair-follicle-derived tumors in comparison with nonfollicular epithelial skin tumors. J Invest Dermatol 1995;104:396-400.
22. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30.
23. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140:209-21.
24. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464:431-5.
25. Kim S-H, Ricci MS, El-Deiry WS. Mcl-1: a gateway to TRAIL sensitization. Cancer Res 2008;68:2062-4. (Pubitemid 351521775)
26. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, Wang W, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80. (Pubitemid 47001783)
27. Strumberg D, Voliotis D, Moeller JG, Hilger RA, Richly H, Kredtke S, et al. Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors. Int J Clin Pharmacol Ther 2002;40:580-1.
28. Monslow J, Sato N, Mack JA, Maytin EV. Wounding-induced synthesis of hyaluronic acid in organotypic epidermal cultures requires the release of heparin-binding egf and activation of the EGFR. J Invest Dermatol 2009;129:2046-58.
29. Katiyar SK. A single physiologic dose of ultraviolet light exposure to human skin in vivo induces phosphorylation of epidermal growth factor receptor. Int J Oncol 2001;19:459-64.
30. Pierceall WE, Goldberg LH, Tainsky MA, Mukhopadhyay T, Ananthaswamy HN. Ras gene mutation and amplification in human nonmelanoma skin cancers. Mol Carcinog 1991;4:196-202.
31. Pierceall WE, Mukhopadhyay T, Goldberg LH, Ananthaswamy HN. Mutations in the p53 tumor suppressor gene in human cutaneous squamous cell carcinomas. Mol Carcinog 1991;4:445-9.
32. Spencer JM, Kahn SM, Jiang W, DeLeo VA, Weinstein IB. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131:796-800.
33. Suk JD, Park WS, Kim D-K. Low rates of somatic p53 mutations in keratoacanthomas. J Dermatol Sci 2009;53:72-3.
34. Corominas M, Kamino H, Leon J, Pellicer A. Oncogene activation in human benign tumors of the skin (keratoacanthomas): is HRAS involved in differentiation as well as proliferation? Proc Natl Acad Sci U S A 1989;86:6372-6. (Pubitemid 19210654)
35. Bourre F, Lichtenberger A, Sarasin A. Comparison of spontaneous and ultraviolet-induced mutagenesis on naked SV40 DNA and SV40 virus. Mutat Res 1991;250:49-53.
36. Bourre F, Renault G, Sarasin A. Sequence effect on alkali-sensitive sites in UV-irradiated SV40 DNA. Nucleic Acids Res 1987;15:8861-75.
37. Ling G, Persson A, Berne B, Uhlën M, Lundeberg J, Ponten F. Persistent p53 mutations in single cells from normal human skin. Am J Pathol 2001;159:1247-53. (Pubitemid 32947954)
38. Ståhl PL, Stranneheim H, Asplund A, Berglund L, Pontén F, Lundeberg J. Sun-induced nonsynonymous p53 mutations are extensively accumulated and tolerated in normal appearing human skin. J Invest Dermatol 2011;131:504-8.
39. Lacouture ME, Chapman PB, Ribas A, Sosman JA, Mc Arthur GA, Flaherty K, et al. Presence of frequent underlying RAS mutations in cutaneous squamous cell carcinomas and keratoacanthomas (cuSCC/KA) that develop in patients during vemurafenib therapy. J Clin Oncol 2011;29:8520.
40. Parsons BL, Marchant-Miros KE, Delongchamp RR, Verkler TL, Patterson TA, McKinzie PB, et al. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest 2010;28:364-75.
41. Keohavong P, Mady HH, Gao WM, Siegfried JM, Luketich JD, Melhem MF. Topographic analysis of K- ras mutations in histologically normal lung tissues and tumours of lung cancer patients. Br J Cancer 2001;85:235-41. (Pubitemid 32695745)